logo

Established since 1951, we provide a full range of services as a CDMO for Live biotherapeutic products (LPB).

Contact us

+33 4 71 46 80 00

info@biose.com

24 Avenue Georges Pompidou, 15000 Aurillac, France

Mon - Frid, 8 AM - 5 PM

Closed on Saturday - Sunday.

R&D Platform

From early discovery to CMC development, with a focus on LBP

Our dedicated staff and advanced equipment enable us to identify the strain and processes that are the most suitable for your development. The techniques we use are highly dependent on the Live Biotherapeutic Product’s (LBP’s) future purpose. Nevertheless, for your reference  we’ve included a non-exhaustive list of options for aerobic, anaerobic or GMO strains below:

  • Isolation of specific strains starting from a sample
  • Strain identification using following techniques:
    • Gram coloration (PREVI COLOR)
    • Phenotipic analysis (DIVERSILAB)
    • Genetic analysis (rep-PCR, quantitative PCR, full genome sequencing, RNAseq, comparison of metabolic pathways activation)
  • Gene integration
  • In vitro characterization, including:
    • Resistance to biological substances (bile, gastric pH)
    • Sensitivity to antibiotics, antifungals
    • Membrane properties characterization
    • Growth ability on different carbon sources
    • Adhesion test to human cells (Caco2, HT29, vaginal cell lines…)
    • Pathogens inhibition

« biose industrie’s strength is to integrate industrial constraints in the Research and Development process: our R&D and industrial teams work together on a daily basis allowing constant communication between them. »

This enables a flawless transfer from lab to commercial scale!

Here are a few example of our capabilities:

  • GMP Cell banking (MCB/WCB)
  • Process development and optimization:
    • Culture media and conditions (fermenters from 0.5 to 20 liters working volume)
    • Concentration/purification
    • Cryoprotectants
    • Freeze-drying cycles (freeze-drying capacity from 0.5 to 4 m²)
    • Grinding / milling development
    • Stabilities optimization
  • Finished dosage form development:
    • Tablets, with specific technology to avoid damaging the bacteria during compression
    • Powders
    • Capsules
    • Liquids
  • Stability assessments (assessing influence of different parameters):
    • Temperature (Zone III, IV b) and accelerated stability studies (40+ degrees)
    • Stability modeling
    • Process
    • Packaging, to optimize LBP’s protection